Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib plus bendamustine + rituximab vs bendamustine + rituximab in previously untreated mantle cell lymphoma
CTR20241242Phase 3Active
- Sponsor
- Innovent Biologics
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orelabrutinib in mantle cell lymphoma (MCL), sponsored by Innovent Biologics. Started May 2024; status: active.
02
Drugs
orelabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20241242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241242.